City: Basel

ten23 health combines the latest scientific findings with our proven and tested world-class industry and regulatory expertise to forge new paths for our clients’ needs. We provide our innovative services in a fair and sustainable manner, respecting people’s health and the future of our planet.

Synendos is a new, dynamic neuroscience company developing potentially breakthrough safe and effective therapies for neuropsychiatric disorders. We utilise the modulation of a new drug target in the endocannabinoid system (ECS) that enables restoration of the natural functioning of the brain. Synendos’ lead drug candidate, SYT-510, belongs to a novel class of ECS modulators named Selective Endocannabinoid Re-uptake Inhibitors (SERIs). SERIs represent first in class, new chemical entities that modulate the ECS through a self-limiting mode of action with the potential to deliver meaningful benefits to patients. Synendos’ current focus is on anxiety and mood-related diseases characterized by an endocannabinoid deficiency and with high unmet medical need such as post-traumatic stress disorder (PTSD). We anticipate that SYT-510 will enter clinical studies during 2023 and Synendos will transition to a clinical stage biotech. Synendos closed a Series A round of CHF 24m in April 2021 with a strong syndicate of investors including Kurma Partners, Sunstone Life Science Ventures, Ysios Capital and Bernina BioInvest. In addition, Synendos has raised CHF 4m in grant funding from a variety of sources that have provided a firm validation of the technology, approach and potential success of the company. Synendos is a spin-out from the University of Bern and retains access to the extensive expertise of the ECS within the group of Prof Jürg Gertsch. All of the assets and targets relevant to the company are protected by a robust series of patents filed or granted in all major markets. | Synendos is a new, clinical stage neuroscience company developing potentially breakthrough safe and effective therapies for neuropsychiatric disorders. We utilise the modulation of a new drug target in the endocannabinoid system (ECS) that enables restoration of the natural functioning of the brain. Synendos’ lead drug candidate, SYT-510, belongs to a novel class of ECS modulators named Selective Endocannabinoid Re-uptake Inhibitors (SERIs). SERIs represent first in class, new chemical entities that modulate the ECS through a self-limiting mode of action with the potential to deliver meaningful benefits to patients. Synendos’ current focus is on anxiety and mood-related diseases characterized by an endocannabinoid deficiency and with high unmet medical need such as post-traumatic stress disorder (PTSD). SYT-510 entered Phase 1 clinical studies in February 2024 marking the transition of Synendos into a clinical stage biotech. Synendos closed a Series A round of CHF 24m in April 2021 with a strong syndicate of investors including Kurma Partners, Sunstone Life Science Ventures, Ysios Capital and Bernina BioInvest. In addition, Synendos has raised CHF 4m in grant funding from a variety of sources that have provided a firm validation of the technology, approach and potential success of the company. Synendos is a spin-out from the University of Bern and retains access to the extensive expertise of the ECS within the group of Prof Jürg Gertsch. All of the assets and targets relevant to the company are protected by a robust series of patents filed or granted in all major markets. | Synendos is a clinical stage neuroscience company developing potentially breakthrough safe and effective therapies for neuropsychiatric disorders, such as PTSD. We utilise the modulation of a new drug target in the endocannabinoid system (ECS) that enables restoration of the natural functioning of the brain. Synendos’ lead drug candidate, SYT-510, belongs to a novel class of ECS modulators named Selective Endocannabinoid Re-uptake Inhibitors (SERIs). Synendos’ current focus is on anxiety and mood-related diseases with high unmet medical need. SYT-510 has completed Phase 1 clinical studies and demonstrated an excellent safety profile with promising biomarker data.